araag2/HINT huggingface dataset:
Clinical trial NCT02886559 (phase 1/phase 2, status: unknown status)
Conditions: aml, relapse
ICD codes: C90.02, C90.22, C90.32, C92.32, C95.92, C90.12, C91.02
Drugs: chidamide plus dcag regimen
SMILES: ClCCNC(=O)N(CCCl)N=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women whose age more than 18 and less than 59；

          -  Patients diagnosed as AML according to the 2008 WHO (WHO) myeloid malignant disease
             diagnosis standard;

          -  Patients who relapsed after remission or who can not achieve remission after at least
             two cycle of systemic therapy (including chemotherapy, hematopoietic stem cell
             transplantation, etc.);

          -  ECOG performance status 0-3;

          -  Expected survival time ˃ 3 months;

          -  Patients without serious hearts, lung, liver, kidney disease;

          -  Patients have not received radiotherapy, chemotherapy, targeted therapy or
             hematopoietic stem cell transplantation and other treatment within 4 weeks prior to
             the enrollment;

          -  Patients are able to understand and willing to sign informed consent.

        Exclusion Criteria:

          -  Patients who allergy to the study drug or the drug with similar chemical structure;;

          -  Pregnancy, lactation women and women of childbearing age who do not want to practice
             effective methods of contraception;

          -  Active infection;

          -  Drug abuse, long-term alcohol abuse so as to affect the results of the evaluation of
             patients;

          -  Patients with mental disorders or other conditions can not obtain informed consent,
             can not meet the requirements of the study treatment and procedures;

          -  Patients have clinical significant QTc interval prolongation history (male > 450ms.
             Female >470ms), ventricular heart had tachycardia (VT) and atrial fibrillation (AF),
             II degree heart block, myocardial infarction attack (MI) within 1 year prior to the
             enrollment, congestive heart failure (CHF), patients of coronary heart disease who
             have clinical symptoms and need drug treatment.

          -  Cardiac ultrasound showed that the diastolic pericardial fluid dark area width ˃ 10mm;

          -  Patients have received organ transplantation;

          -  Active bleeding

          -  Patients have new thrombosis, embolism, cerebral hemorrhage and other diseases or
             medical history of patients within 1 year prior to enrollment;

          -  The main organs of the surgery is less than 6 weeks;

          -  Bone marrow hyperplasia and WBC <2.0 * 10^9/L;

          -  Liver function abnormalities (total bilirubin > 1.5 times of upper limit of normal
             range , ALT / AST > 2.5 times of the upper limit of normal range or patients with
             liver involvement whose ALT / AST > 1.5 times of upper limit of normal range), renal
             anomalies (serum creatinine > 1.5 times of upper limit of normal value );

          -  Not suitable for the study according to investigator's assessment.
Clinical trial NCT02907567 (phase 1/phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: ct1812, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Willing and able to provide written informed consent prior to initiation of any
             study-related procedures. For subjects unable to provide written consent, consent will
             be provided by the Person Responsible per local regulations.

          2. Men and women, 50-80 years in age inclusively with a diagnosis of mild to moderate
             Alzheimer's disease according to the 2011 NIA-AA. Women must be neither pregnant nor
             nursing, and are either surgically sterile, postmenopausal or premenopausal using an
             acceptable method of contraception.

          3. Previous decline in cognition for more than six months.

          4. Neuroimaging (MRI) obtained within the previous 6 months or during screening,
             consistent with the clinical diagnosis of Alzheimer's disease.

          5. MMSE 18-26 inclusive.

          6. No active depression and a Geriatric Depression Score (GDS) of < 6.

          7. Modified Hachinski Ischemia score ≤ 4.

          8. Formal education of eight or more years.

          9. Living at home or in a community setting (assisted living) without continuous nursing
             care. Each subject must have a reliable caregiver who sees them at least 3 times
             weekly, can oversee the administration of study drug, and is willing and able to
             participate in all clinic visits and some study procedures. Responsible caregiver must
             provide written informed consent to participate.

         10. Concurrent use of acetylcholinesterase inhibitors or memantine must be stable for 90
             days prior to screening and not expected to change.

        Exclusion Criteria:

          1. History of or screening brain MRI scan indicative of significant abnormality,
             including, but not limited to, prior hemorrhage or infarct > 1 cm3, >3 lacunar
             infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation,
             subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor
             such as meningioma).

          2. Clinical or laboratory findings consistent with:

               1. Other primary degenerative dementia,

               2. Other neurodegenerative condition

               3. Seizure disorder

               4. Other infectious, metabolic or systemic diseases affecting the central nervous
                  system

          3. A current DSM-V diagnosis of active major depression, schizophrenia or bipolar
             disorder.

          4. Clinically significant, advanced or unstable disease that may interfere with outcome
             measures, and which may bias the assessment of the clinical or mental status of the
             patient or put the patient at special risk
Clinical trial NCT02909452 (phase 1, status: unknown status)
Conditions: neoplasms, neoplasms, glandular and epithelial, neoplasms by histologic type, bronchial neoplasms, lung neoplasms, respiratory tract neoplasms, thoracic neoplasms, digestive system neoplasms, endocrine gland neoplasms, carcinoma, non-small-cell lung, lung diseases, breast diseases, renal neoplasm, solid tumors
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, D49.0, C26.9, D13.9, C75.9, D35.9, D44.9, D35.7, D49.7, Z85.858, D02.20, D02.21, D02.22, J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, S20.00XS, S20.111S, S20.112S, S20.119S, S20.00XA, S20.00XD, S20.111A
Drugs: entinostat, pembrolizumab
SMILES: NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Completed Study SNDX-275-0140 (NCT02897778)

          2. Any AE or toxicity experienced in Study SNDX-275-0140 (NCT02897778) is resolved to
             less than or equal to Grade 1

          3. Continues to meet inclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time
             of entry into this study

        Exclusion Criteria:

          1. Completed Study SNDX-275-0140 (NCT02897778) more than 30 days prior to Cycle 1 Day 1
             of this study

          2. Continues to meet exclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time
             of entry into this study
Clinical trial NCT02912234 (phase 1, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: apixaban, clarithromycin
SMILES: COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

          1. Signed Informed Consent

          2. Target population: Healthy subjects as determined by medical history, surgical
             history, physical examination, vital signs, electrocardiogram (ECG), and clinical
             laboratory tests including coagulation parameters.

          3. Subjects with body mass index of 18 to 30 kg/m2, inclusive

          4. Women must not be breast feeding, have a negative serum or urine pregnancy test and
             must agree to follow instructions for method(s) of contraception for the duration of
             treatment with study treatments apixaban and clarithromycin plus 5 half-lives of study
             treatments apixaban and clarithromycin plus 30 days (duration of ovulatory cycle) for
             a total of 33 days post-treatment completion.

          5. Men who are sexually active with WOCBP must agree to follow instructions for method(s)
             of contraception for the duration of treatment with study treatments apixaban and
             clarithromycin plus 5 half-lives of the study treatment plus 30 days for a total of 33
             days post-treatment completion. In addition, male participants must be willing to
             refrain from sperm donation during this time.

        Exclusion Criteria:

          1. History of any significant medical illness, drug allergy including allergy to
             apixaban, FXa inhibitors (and/or their excipients), clarithromycin, macrolides, and/or
             related compounds. History of substance abuse and use of nicotine containing products
             and/or alcohol abuse.

          2. History of coagulopathy, prolonged or unexplained clinically significant bleeding, or
             frequent unexplained bruising or thrombus formation, including hypermenorrhea,
             intra-cranial hemorrhage, family history of bleeding disorders in first degree
             relatives, and/or any adverse reaction to anticoagulants or antiplatelet agents that
             resulted in excessive bleeding.

          3. History of recurrent neurological or gastrointestinal disorders, including insomnia,
             chronic headaches, dizziness, gastroesophageal reflux disease, cholecystectomy,
             gastric ulcers and/or Gilbert's syndrome.

          4. History of antibiotic induced secondary infections, including candidiasis.

          5. Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG, or clinical laboratory tests beyond what is
             consistent with the target population.
Clinical trial NCT02914353 (phase 1, status: completed)
Conditions: arthroplasty, replacement, knee
ICD codes: Z79.890, Z96.693, Z47.1, Z95.4, Z96.691, Z96.692, T82.320S
Drugs: ep=7041, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, non-smoker (no use of tobacco products within 3 months prior to
             screening), ≥18 and ≤60 years of age, with Body Mass Index (BMI) > 18.5 and < 32.0
             kg/m2 and a weight of at least 60 kg but not greater than 100 kg.

          -  Healthy as defined by:

               1. No history of abnormal bleeding episodes, e.g. nosebleeds, or abnormally heavy
                  periods, or extensive bleeding after injury, surgery or dental work.

               2. A normal short physical examination and normal vital signs (heart rate (HR),
                  blood pressure (BP) and tympanic body temperature).

               3. Normal laboratory tests (hematology, biochemistry, urinalysis, coagulation tests
                  (aPTT and PT).

               4. the absence of clinically significant illness and surgery within 4 weeks prior to
                  dosing.

               5. the absence of clinically significant history of neurological, endocrinal,
                  cardiovascular, pulmonary, hematological, immunologic, psychiatric,
                  gastrointestinal, renal, hepatic, and metabolic disease.

        Exclusion Criteria:

          -  Any clinically significant abnormality or abnormal laboratory test results found
             during medical screening which, at the investigator's discretion, warrants exclusion
             or positive test for hepatitis B, hepatitis C, or HIV.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days
             prior to drug administration.

          -  Positive pregnancy test at screening or check-in (Day -1).

          -  Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood
             pressure lower than 90 or over 160 mmHg, diastolic blood pressure lower than 50 or
             over 90 mmHg, or heart rate less than 40 or over 100 bpm) at screening or check-in
             (Day -1).

          -  Participation in a clinical trial involving the administration of an investigational
             or marketed drug within 30 days (90 days for biologics), or five (5) half-lives,
             whichever is longer, prior to the first dosing or concomitant participation in an
             investigational study involving no drug administration.

          -  Hemoglobin or hematocrit clinically significantly less than lower limits of normal at
             screening.
Clinical trial NCT02915250 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: biochaperone® combo, humalog® mix25, humalog®, lantus®, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject aged 18-70 years (both inclusive)

          -  Type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months

          -  HbA1c level between 7.5% and 9.5% (both inclusive)

          -  Body mass index between 20.0 and 40.0 kg/m2 (both inclusive)

          -  Treated with once daily injections with insulin glargine U-100 for ≥ 3 months prior to
             screening

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Known or suspected allergy to the IMPs or related products

          -  Previous participation in this trial. Participation is defined as randomised.

          -  Receipt of any medicinal product in clinical development within 60 days prior to this
             trial.

          -  Clinically significant abnormal haematology, biochemistry, urinalysis or coagulation
             screening tests, as judged by the Investigator considering the underlying disease

          -  Supine blood pressure at screening outside the range of 90-160 mmHg for systolic or
             50-95 mmHg for diastolic and/or resting supine heart rate outside the range 50-90
             beats per minute. This exclusion criterion also pertains to subjects being on
             antihypertensives.

          -  Current treatment with premixed or intermediate insulin products, or with long acting
             insulins other than insulin glargine U-100. The use of short or rapid acting prandial
             insulin products will be allowed provided their use has been stable for ≥ 3 months
             prior to screening.

          -  Use of GLP-1 receptor agonists or oral antidiabetic drugs (OADs) other than stable
             intake of metformin alone or metformin in combination with a DPP-4 inhibitor within 4
             weeks prior to screening

          -  Women of child bearing potential not willing to use contraceptive methods.
Clinical trial NCT02915523 (phase 1/phase 2, status: unknown status)
Conditions: epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer
ICD codes: H18.523, H18.521, H18.522, H18.529, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02, C57.00, C57.01, C57.02
Drugs: entinostat, avelumab, placebo
SMILES: NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed epithelial ovarian, fallopian tube, or
             peritoneal cancer

          -  Recurrent or progressive disease on or after initial platinum-based chemotherapy

          -  Evidence of measurable disease based on imaging studies within 28 days before the
             first dose of study drug

          -  Previously received at least 3, but no more than 6, lines of therapy including at
             least 1 course of platinum-based therapy

          -  Patient must have acceptable, applicable laboratory requirements

          -  Patients may have a history of brain metastasis provided certain protocol criteria are
             met

          -  Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy
             to Grade ≤1 (except alopecia or neuropathy)

          -  Able to understand and give written informed consent and comply with study procedures.

        Exclusion Criteria:

          -  Non-epithelial ovarian carcinomas or ovarian tumors with low malignant potential
             (i.e., borderline tumors)

          -  Another known malignancy that is progressing or requires active treatment (excluding
             adequately treated basal cell carcinoma or cervical intraepithelial neoplasia/cervical
             carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed, as
             long as there is no active disease within the prior 5 years.

          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
             of immunosuppressive therapy within 7 days prior to enrollment.

          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent

          -  Previously treated with a histone deacetylase inhibitor (i.e., vorinostat, belinostat,
             romidepsin, panobinostat), PD-1/PD-L1-blocking antibody (i.e., atezolizumab,
             nivolumab, pembrolizumab), or a cytotoxic T-lymphocyte associated protein-4 (CTLA-4)
             agent

          -  Currently enrolled in (or completed) another investigational drug study within 30 days
             prior to study drug administration

          -  A medical condition that precludes adequate study treatment or increases patient risk
Clinical trial NCT02920424 (phase 1, status: withdrawn)
Conditions: lupus erythematosus, systemic
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: jnj-56022473, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the decision is based on a change in the benefit risk assessment of this drug for the lupus
    population targeted in this study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have a body weight in the range of 40 to 100 kilogram (kg), inclusive,
             and have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m^2),
             inclusive, at screening

          -  Subjects eligible for enrollment in this study must qualify as follows: a) must meet
             Systemic Lupus International Collaborating Clinics (SLICC) criteria for diagnosis of
             lupus and b) must have at least one non-serologic clinical activity defined by the
             Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) within 3 months
             prior to first study agent administration

          -  Have a positive gene signature score during screening, prior to first administration
             of study agent

          -  Subjects using allowed pre-existing lupus treatments, if stable for at least 6 weeks
             prior to the first dose of study medication:

               1. oral corticosteroids equivalent to an average dose up to or equal to (<=) 10
                  milligram (mg) of prednisone/day

               2. use of antimalarials (such as chloroquine or hydroxychloroguine) for at least 8
                  weeks

               3. maximum of 1 non-corticosteroid immunosuppressive drug

        Exclusion Criteria:

          -  Subject with history or suspected occurrence of drug-induced systemic lupus
             erythematosus (SLE)

          -  Subject has unstable lupus nephritis and/ or has active Central nervous system (CNS)
             lupus or history of severe CNS lupus, including but not limited to seizures,
             psychosis, transverse myelitis, CNS vasculitis and optic neuritis

          -  Major surgery prior to, and, if planned, during and shortly after the study is not
             eligible

          -  Subject has or has had an acute illness, including a common cold, within 2 weeks prior
             to the study agent administration or has had a major illness or hospitalization within
             4 months prior to the screening visit

          -  Any other inflammatory diseases that might confound the evaluations of efficacy are
             excluded
Clinical trial NCT02935647 (phase 1, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: diprivan
SMILES: CC(C)C1=CC=CC(C(C)C)=C1O
Eligibility criteria:

        Inclusion Criteria:

          -  • Diagnosis of Major Depressive Disorder (MDD) or bipolar Disorder (I or II, most
             recent episode must be depression

               -  Failed at least 2 anti-depressant treatments and no ECT in past 6 months

               -  Age between 18-55 years

               -  BMI < 35

               -  Hamilton Rating Scale for Depression (HSRD) score > 18

               -  Quick Inventory of Depression Scale (QIDS) score > 10.

        Exclusion Criteria:

          -  • Diagnosis of primary psychotic disorder, dysthymia, or personality disorder

               -  Significant pre-morbid cognitive impairment

               -  Hypertension and current use of ACE inhibitor or AR blocker medications

               -  Symptomatic coronary artery disease or congestive heart failure

               -  History of transient ischemic or neurologic signs during the past year

               -  History of or susceptibility to malignant hyperthermia

               -  Contraindication to isoflurane or propofol anesthesia (as determined by
                  anesthesiologist)

               -  Diabetes requiring insulin

               -  Poor kidney function

               -  Chronic use of benzodiazepines or opioids

               -  Individuals incompetent to provide consent (e.g. catatonic, psychotic).
Clinical trial NCT02935725 (phase 1, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: low dose aut00206 800mg, high dose aut00206 2000 mg, placebo, ketamine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male aged 18 to 45 years, inclusive at Visit 1.

          -  Healthy on the basis of medical history, psychiatric history, physical examination,
             vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry and
             urinalysis within 6 weeks of Visit 2.

          -  Right-handed.

          -  Not a regular smoker (maximum 5 cigarettes per week or equivalent).

        Exclusion Criteria:

          -  History of, or current condition of, migraine headaches or has undergone operations to
             the head.

          -  History of significant claustrophobia.